{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:27:13Z","timestamp":1790242033098,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2016,5]]},"abstract":"\n Background and objectives<\/jats:title>\n There is a disproportionate burden of human papillomavirus (HPV) \u2013related genital tract disease in patients with CKD and kidney transplantation; therefore, the potential effect of the quadrivalent HPV vaccine (Gardasil; Merck GmbH, Darmstadt, Germany) is profound. Immune abnormalities associated with CKD and immunosuppression may prevent optimal vaccine response. Our objective was to determine antibody response to the HPV vaccine in adolescent girls with CKD.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n \n This cohort study conducted from 2008 to 2012 included 57 girls aged 9\u201321 years old with CKD (\n n<\/jats:italic>\n =25), on dialysis (\n n<\/jats:italic>\n =9), or with status postkidney transplantation (\n n<\/jats:italic>\n =23) who received the standard three\u2013dose vaccine series of the HPV vaccine recruited from two pediatric nephrology clinics. Antibody levels to HPV genotypes 6, 11, 16, and 18 were measured before vaccine dose 1 (baseline), <12 months after vaccine dose 3 (blood draw 2), and \u226512 months after vaccine dose 3 (blood draw 3). Seropositivity was defined as antibody level above an established threshold for each HPV genotype. Not all participants completed three blood draws.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Antibody response to all four HPV genotypes was 100% in the CKD and dialysis groups with samples drawn at <12 and \u226512 months after dose 3 of the HPV vaccine. Among patients with transplants, the percentages of patients achieving seropositivity were significantly lower at blood draw 2 for HPV genotypes 6 (63.6%;\n P<\/jats:italic>\n =0.003), 11 (63.6%;\n P<\/jats:italic>\n =0.003), and 18 (72.7%;\n P<\/jats:italic>\n =0.02) and blood draw 3 for HPV genotypes 6 (62.5%;\n P<\/jats:italic>\n =0.02), 11 (50%;\n P<\/jats:italic>\n =0.001), 16 (75%;\n P<\/jats:italic>\n =0.04), and 18 (50%;\n P<\/jats:italic>\n =0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Antibody response to the quadrivalent recombinant HPV vaccine was robust and sustained in girls and young women with CKD and on dialysis. A less robust response to the vaccine was observed among those with a kidney transplant. Additional study is needed to determine if vaccination before kidney transplantation or an alternative vaccination regimen would benefit transplant recipients.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.09690915","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T09:23:19Z","timestamp":1460107399000},"page":"776-784","source":"Crossref","is-referenced-by-count":40,"title":["Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD"],"prefix":"10.2215","volume":"11","author":[{"given":"Delphine R.","family":"Nelson","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Neu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Amaral","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, University of Pennsylvania School of Medicine and the Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Batisky","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Fadrowski","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,4,7]]},"reference":[{"key":"B2-20230813","first-page":"959","article-title":"Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.","volume":"12","author":"Dias","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"Suppl 1","key":"B4-20230813","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ndt\/10.supp1.74","article-title":"Malignancies after renal transplantation: The EDTA-ERA registry experience.","volume":"10","author":"Brunner","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1432-2277.2006.00383.x","article-title":"Excess risk of cancer in renal transplant patients.","volume":"19","author":"Kessler","year":"2006","journal-title":"Transpl Int"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-642-78771-3_6","article-title":"Skin cancer and warts in immunosuppressed renal transplant recipients.","volume":"139","author":"Leigh","year":"1995","journal-title":"Recent Results Cancer Res"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States.","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0272-6386(12)80375-1","article-title":"Hepatitis B virus infection in chronic uremia: Long-term follow-up of a two-step integrated protocol of vaccination.","volume":"23","author":"Marangi","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0041-1345(00)00914-3","article-title":"Factors influencing response to hepatitis B virus vaccination in hemodialysis patients.","volume":"32","author":"Sezer","year":"2000","journal-title":"Transplant Proc"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00866312","article-title":"Response to measles-mumps-rubella vaccine in children on dialysis.","volume":"6","author":"Schulman","year":"1992","journal-title":"Pediatr Nephrol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00365590310008749","article-title":"The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients.","volume":"37","author":"Cavdar","year":"2003","journal-title":"Scand J Urol Nephrol"},{"key":"B13-20230813","first-page":"245","article-title":"Influenza antibody titers after vaccination of chronic renal failure patients; before and during hemodialysis, or on continuous ambulatory peritoneal dialysis.","volume":"15","author":"Suga","year":"1990","journal-title":"Tokai J Exp Clin Med"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/oxfordjournals.ndt.a027313","article-title":"Pneumococcal vaccine in children and young adults with chronic renal disease.","volume":"11","author":"Fuchshuber","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/ajkd.2001.29223","article-title":"A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients.","volume":"38","author":"Kr\u00fcger","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B16-20230813","first-page":"256","article-title":"Immunization guidelines for pediatric renal disease.","volume":"18","author":"Fivush","year":"1998","journal-title":"Semin Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial.","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/petr.12034","article-title":"Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: A report of the North American Pediatric Renal Trials and Collaborative Studies.","volume":"17","author":"Smith","year":"2013","journal-title":"Pediatr Transplant"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial.","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.jrn.2011.10.020","article-title":"Effect of uremia on structure and function of immune system.","volume":"22","author":"Vaziri","year":"2012","journal-title":"J Ren Nutr"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1525-139X.2006.00175.x","article-title":"Neutrophil dysfunction and infection risk in end-stage renal disease.","volume":"19","author":"Chonchol","year":"2006","journal-title":"Semin Dial"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2215\/CJN.01290308","article-title":"Epidemiology of acute infections among patients with chronic kidney disease.","volume":"3","author":"Dalrymple","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/14760584.3.3.291","article-title":"Varicella zoster virus: Vaccination and implications in children with renal failure.","volume":"3","author":"Fadrowski","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1016\/j.vaccine.2014.09.038","article-title":"Vaccine administration in children with chronic kidney disease.","volume":"32","author":"Esposito","year":"2014","journal-title":"Vaccine"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/petr.12226","article-title":"Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients.","volume":"18","author":"Gomez-Lobo","year":"2014","journal-title":"Pediatr Transplant"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/ajt.12329","article-title":"Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients.","volume":"13","author":"Kumar","year":"2013","journal-title":"Am J Transplant"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.","volume":"200","author":"Schiller","year":"2009","journal-title":"J Infect Dis"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1016\/j.vaccine.2014.08.004","article-title":"Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.","volume":"32","author":"Brown","year":"2014","journal-title":"Vaccine"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4161\/hv.7.2.13948","article-title":"The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.","volume":"7","author":"Brown","year":"2011","journal-title":"Hum Vaccin"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/jcm4061229","article-title":"Cutaneous squamous cell carcinomas in organ transplant recipients.","volume":"4","author":"Chockalingam","year":"2015","journal-title":"J Clin Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201605000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:46:18Z","timestamp":1786369578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201605000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09690915","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,7]]}}}